The JMJD7 Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human non-small cell lung cancer (NSCLC) line NCI-H1975. This gene-edited product features targeted disruption of the JMJD7 locus, resulting in a heterogeneous pool of cells with loss-of-function mutations across the JMJD7 gene. As a polyclonal population, it provides a biologically relevant model for studying JMJD7??s role without the clonal variations often introduced during single-cell isolation. The polyclonal format preserves the cellular diversity inherent in the edited population, making it suitable for experiments where population-level responses are critical. This knockout model is intended for biomedical research applications focusing on lung adenocarcinoma and the molecular pathways governing translation and chromatin remodeling.
The parental NCI-H1975 cell line is a well-characterized human lung adenocarcinoma model originating from a non-smoking female patient. These cells carry activating mutations in the epidermal growth factor receptor (EGFR), specifically L858R and T790M, which are clinically relevant drivers of tumor growth and acquired resistance to first-generation EGFR tyrosine kinase inhibitors. The dual mutation status makes NCI-H1975 an essential tool for investigating mechanisms of EGFR-targeted therapy resistance and for developing next-generation treatment strategies. In the context of JMJD7 knockout, this genetic background enables the dissection of how JMJD7-dependent processes intersect with EGFR signaling, translation control, and cellular adaptation to oncogenic stress.
JMJD7 encodes a Jumonji C (JmjC) domain-containing hydroxylase with putative functions in ribosomal protein hydroxylation and histone modification. As part of the translation regulatory network, JMJD7 is implicated in the hydroxylation of ribosomal proteins such as RPL8, potentially modulating ribosome biogenesis and translation efficiency. It has also been linked to histone H3 demethylation, suggesting a role in epigenetic gene regulation. JMJD7 operates downstream of hypoxic signaling via HIF-1?? and nutrient-sensing mTOR signaling, both frequently dysregulated in cancer. The protein interacts with ribosomal subunits and JmjC domain family members, integrating environmental cues with protein synthesis and gene expression. Representative pathway components include eukaryotic initiation factors (eIFs) and other ribosomal proteins that collectively govern translational output under cellular stress.
In the NCI-H1975 lung adenocarcinoma context, JMJD7 may influence tumor cell proliferation, survival, and drug responsiveness, particularly under conditions that mimic the tumor microenvironment such as hypoxia or mTOR hyperactivity. The EGFR L858R/T790M mutations drive constitutive proliferative signaling, and JMJD7-dependent translation regulation could contribute to the adaptive responses that sustain cancer cell viability during kinase inhibitor treatment. By ablating JMJD7 in this genetically defined background, researchers can directly assess its contribution to EGFR-dependent growth, apoptosis evasion, and migration. This knockout model thus serves as a specialized platform for exploring how ribosomal protein modifications impinge on oncogenic signaling networks in NSCLC.
Typical research applications of the JMJD7 Knockout NCI-H1975 Polyclonal Cells include functional studies using proliferation assays (MTT), colony formation assays, and cell migration/invasion transwell systems to quantify the impact of JMJD7 loss on cancer cell behavior. The cells are also suitable for western blotting and RT-qPCR analysis of downstream targets and pathway markers, as well as drug sensitivity screens with EGFR inhibitors such as osimertinib or erlotinib to identify synthetic lethal interactions. Researchers can employ these polyclonal knockout cells to validate JMJD7 as a potential therapeutic target or to map its role in translation-mediated drug resistance. For further technical details and batch-specific validation information, please contact Ascent Research.
